We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals

128 hedge funds and large institutions have $626M invested in Olema Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

305% more call options, than puts

Call options by funds: $1.93M | Put options by funds: $477K

50% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 34

12% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 26

3.18% more ownership

Funds ownership: 100.34%103.52% (+3.2%)

2% more funds holding

Funds holding: 126128 (+2)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1% less capital invested

Capital invested by funds: $635M → $626M (-$8.72M)

Holders
128
Holders Change
+2
Holders Change %
+1.59%
% of All Funds
1.85%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
29
Increased
51
Reduced
34
Closed
26
Calls
$1.93M
Puts
$477K
Net Calls
+$1.46M
Net Calls Change
+$1.31M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$98.9M
PBA
2
Paradigm Biocapital Advisors
New York
$85.5M
DTC
3
Deep Track Capital
Connecticut
$43.3M +$8.4M +774,581 +24%
BlackRock
4
BlackRock
New York
$43.3M +$8.49M +782,964 +24%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$34.8M +$34.8M +3,211,927 New
LGM
6
Logos Global Management
California
$34.7M -$12.7M -1,175,000 -27%
Vanguard Group
7
Vanguard Group
Pennsylvania
$29.7M +$3.63M +334,976 +14%
MB
8
MPM BioImpact
Massachusetts
$28.7M +$7.6M +701,177 +36%
State Street
9
State Street
Massachusetts
$21.1M -$13.3M -1,230,450 -39%
VC
10
Vivo Capital
California
$20.3M
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$18.2M -$2.72M -251,233 -13%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$11.5M +$2.39M +220,754 +26%
CS
13
Candriam SCA
Luxembourg
$11.5M +$7.65M +705,655 +200%
PCH
14
Polar Capital Holdings
United Kingdom
$10.8M +$2.71M +250,000 +33%
Wellington Management Group
15
Wellington Management Group
Massachusetts
$9.79M +$755K +69,644 +8%
WP
16
Woodline Partners
California
$9.22M +$1.11M +102,275 +14%
GPP
17
Great Point Partners
Connecticut
$8.62M +$8.64M +796,880 New
Victory Capital Management
18
Victory Capital Management
Texas
$8.38M +$1.78M +164,143 +27%
BC
19
Boxer Capital
California
$7.03M +$7.05M +650,000 New
Marshall Wace
20
Marshall Wace
United Kingdom
$6.37M +$447K +41,193 +8%
GTC
21
Ghost Tree Capital
New York
$5.95M +$3.8M +350,000 +175%
SCM
22
Silverarc Capital Management
Massachusetts
$5.92M +$342K +31,546 +6%
Ameriprise
23
Ameriprise
Minnesota
$4.77M +$1.39M +127,820 +41%
Goldman Sachs
24
Goldman Sachs
New York
$4.34M -$390K -35,926 -8%
Northern Trust
25
Northern Trust
Illinois
$3.72M -$55K -5,075 -1%

OLMA Hedge Fund Activity: Q2 2024 in Review

128 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q2 2024, worth a combined $626M — down 1.4% from $635M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new OLMA positions and 26 closed out — a net gain of 3 holders — while 51 added to existing stakes and 34 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $34.8M. The largest seller was State Street, cutting an estimated $13.3M.

  • 128 institutional investors held Olema Pharmaceuticals (OLMA) as of Q2 2024, up from 126 in Q1 2024.
  • Funds reported $626M of Olema Pharmaceuticals stock for Q2 2024, down 1.4% quarter-over-quarter.
  • 29 funds opened new Olema Pharmaceuticals positions in Q2 2024 and 26 closed out, a net change of +3 holders.
  • The largest Olema Pharmaceuticals buyer in Q2 2024 was Point72 Asset Management, an estimated $34.8M added.
  • The largest Olema Pharmaceuticals seller in Q2 2024 was State Street, an estimated $13.3M sold.

Based on aggregated 13F filings for Q2 2024.